Correction to: BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1758-9193

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Correction to: BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease ; volume:14 ; number:1 ; day:20 ; month:1 ; year:2022 ; pages:1 ; date:12.2022
Alzheimer's research & therapy ; 14, Heft 1 (20.1.2022), 1, 12.2022

Creator: Kim, Jun Pyo
Kim, Bo-Hyun
Bice, Paula J.
Seo, Sang Won
Bennett, David A.
Saykin, Andrew J.
Nho, Kwangsik

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13195-022-00960-6

URN: urn:nbn:de:101:1-2022050122100871808355

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 5:33 AM UTC

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Kim, Jun Pyo
Kim, Bo-Hyun
Bice, Paula J.
Seo, Sang Won
Bennett, David A.
Saykin, Andrew J.
Nho, Kwangsik
SpringerLink (Online service)

Other Objects (12)

BMI1 is associated with CS8F amyloid-β and rates of cognitive decline in Alzheimer’s disease

Plaque complement activation and cognitive loss in Alzheimer's disease

Single-nucleus RNA velocity reveals critical synaptic and cell-cycle dysregulations in neuropathologically confirmed Alzheimer’s disease

Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction

miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease

Protein farnesylation is upregulated in Alzheimer’s human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer’s model mice

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Epistatic effects of IGHG and FCGRIIB genes on the development of Alzheimer’s disease in African Americans

TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease

Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease

Effects of brain microRNAs in cognitive trajectory and Alzheimer’s disease

Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer’s disease

BMI1 is associated with CS8F amyloid-β and rates of cognitive decline in Alzheimer’s disease

Plaque complement activation and cognitive loss in Alzheimer's disease

Single-nucleus RNA velocity reveals critical synaptic and cell-cycle dysregulations in neuropathologically confirmed Alzheimer’s disease

Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction

miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease

Protein farnesylation is upregulated in Alzheimer’s human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer’s model mice

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Epistatic effects of IGHG and FCGRIIB genes on the development of Alzheimer’s disease in African Americans

TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease

Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease

Effects of brain microRNAs in cognitive trajectory and Alzheimer’s disease

Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer’s disease

BMI1 is associated with CS8F amyloid-β and rates of cognitive decline in Alzheimer’s disease

Plaque complement activation and cognitive loss in Alzheimer's disease

Single-nucleus RNA velocity reveals critical synaptic and cell-cycle dysregulations in neuropathologically confirmed Alzheimer’s disease

Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction

miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease

Protein farnesylation is upregulated in Alzheimer’s human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer’s model mice

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Epistatic effects of IGHG and FCGRIIB genes on the development of Alzheimer’s disease in African Americans

TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease

Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease

Effects of brain microRNAs in cognitive trajectory and Alzheimer’s disease

Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer’s disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read and agree to the privacy policy for the collection of personal data.*

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Correction to: BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease

Show object

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

BMI1 is associated with CS8F amyloid-β and rates of cognitive decline in Alzheimer’s disease

Plaque complement activation and cognitive loss in Alzheimer's disease

Single-nucleus RNA velocity reveals critical synaptic and cell-cycle dysregulations in neuropathologically confirmed Alzheimer’s disease

Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction

miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease

Protein farnesylation is upregulated in Alzheimer’s human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer’s model mice

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Epistatic effects of IGHG and FCGRIIB genes on the development of Alzheimer’s disease in African Americans

TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease

Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease

Effects of brain microRNAs in cognitive trajectory and Alzheimer’s disease

Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer’s disease

BMI1 is associated with CS8F amyloid-β and rates of cognitive decline in Alzheimer’s disease

Plaque complement activation and cognitive loss in Alzheimer's disease

Single-nucleus RNA velocity reveals critical synaptic and cell-cycle dysregulations in neuropathologically confirmed Alzheimer’s disease

Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction

miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease

Protein farnesylation is upregulated in Alzheimer’s human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer’s model mice

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Epistatic effects of IGHG and FCGRIIB genes on the development of Alzheimer’s disease in African Americans

TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease

Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease

Effects of brain microRNAs in cognitive trajectory and Alzheimer’s disease

Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer’s disease

BMI1 is associated with CS8F amyloid-β and rates of cognitive decline in Alzheimer’s disease

Plaque complement activation and cognitive loss in Alzheimer's disease

Single-nucleus RNA velocity reveals critical synaptic and cell-cycle dysregulations in neuropathologically confirmed Alzheimer’s disease

Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction

miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease

Protein farnesylation is upregulated in Alzheimer’s human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer’s model mice

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Epistatic effects of IGHG and FCGRIIB genes on the development of Alzheimer’s disease in African Americans

TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease

Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease

Effects of brain microRNAs in cognitive trajectory and Alzheimer’s disease

Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer’s disease

Related objects

Reset password